Knowledge Hub
Knowledge Hub
Patients on octreotide were switched to a new funded brand in late 2021. NECNZ asked nurses and patients to help monitor any side effects.
In late 2021 patients on octreotide were switched to a new funded brand. To help us monitor any side-effects or differences in how patients responded, NECNZ asked nurses to complete a short survey.
The survey is for nurses, but if you're a patient on octreotide, please help us by talking to your nurse about the survey and asking them to complete it every time there's something good or bad to report.
Honouring a legacy: Malcolm Legget MNZM
Associate Professor Dr Malcolm Legget was awarded the MNZM for services to neuroendocrine cancer care in New Zealand.
Waikato clinicians publish rare renal NET case in international oncology journal
A Waikato Hospital and University of Auckland team co-authored a 2025 case report on a renal neuroendocrine tumour causing Cushing's syndrome, published in Case Reports in Oncology.
Gallium-68 Dotatate PET-CT scans now accessible onboard Mobile Imaging
Mobile Health Group and Mercy Radiology have rolled out Gallium-68 Dotatate PET-CT scans on a mobile imaging unit, bringing advanced NET diagnostics closer to home.
Lanreotide now funded in New Zealand for neuroendocrine tumours
From 1 March 2025 Pharmac funds lanreotide (Mytolac) for NETs and related conditions, giving Kiwis a second somatostatin analogue option.